
    
      Phase IV, multicenter, prospective observational study in a real world (RW) setting, designed
      to observe the utilization and effectiveness of PI3K-inhibitor treatment, and HRQoL of
      patients with CLL/SLL/FL outside the context of a clinical trial.
    
  